INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

IRDOpus Genetics, Inc.

CIK 0001228627

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 3
Max Insider Score38
Connections4with evidence

IRD · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
30
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL$2.76M
556.0K sh
Sep 30, 2026Oct 2, 2026
traded Sep 30, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    JEFFREY J. KIMBELL & ASSOCIATES, INC.LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks · Dec 11, 2025
  • ← Insider ofevidence
    Foundation Fighting Blindness, Inc.
34
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL
$7.39M
1.70M sh
May 18, 2026
May 20, 2026
traded May 18, 2026
+2d
SEC FORM 4

Evidence

38
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL$8.60M
4.00M sh
Dec 9, 2025Dec 11, 2025
traded Dec 9, 2025
+2dSEC FORM 4

Evidence

Director, See Remarks · Dec 11, 2025

Lobbying

$30K reported · de-duplicated
2026 Q2 $15K via firms2026 Q1 $15K via firms
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.$15K2026 Q1 · posted Aug 26, 2026 · Health issues
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.$15K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.